Visiting Lecturer Mark Barnes ’84, a leading expert on the laws governing federal research funding, recently discussed his work at a Solomon Center talk.

As hospice care is increasingly dominated by private equity firms, an antitrust response, while necessary, has the potential to normalize the language of the market as the default mode for discussing…

This cross-sectional study examines trends in the introduction and enactment of state-level palliative legislation, categorizes legislative content, and maps distribution across states and regions fro...

A new FDA program is being promoted as a tool to facilitate the development and approval of therapies that are important for society. But it risks undermining regulatory innovation and trust in the...

A new Yale study investigates the quality of cancer care among those diagnosed with cancer during or immediately after incarceration.

Clear Statements is a recurring series by Abbe R. Gluck on civil litigation and the modern regulatory and statutory state. Verbs, verbs, verbs. Court-watchers hoping for fireworks over the reach of […...

A new paper by Solomon Center researchers says Connecticut needs reliable data to expand access to pediatric palliative care.

Former FEMA administrator Deanne B. Criswell, in a Solomon Center talk, said that disaster response is a fraction of what the agency does.

A key sticking point in the government shutdown debate is the upcoming reductions in the premium tax credit (PTC), particularly how the credit declines as in…

In this Article, Yaron Covo argues that disability rights law in the United States is shaped not only by civil rights statutes but also by contract law doctrines. Contract law surfaces in the disabili...

Language services are essential for health equity and good patient health outcomes, but recent executive actions threaten to undermine this vital resource.

Visiting Professor John V. Jacobi addressed state policy reform and the future of disability law.

"A parent should not have to do end-of-life measures for their child," says Carolyn Torello.

Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, an...

This cohort study evaluates the quality of cancer care received by people with a history of incarcaration compared with those who have not been incarcerated in the US.

Clear Statements is a recurring series by Abbe R. Gluck on civil litigation and the modern regulatory and statutory state. As most SCOTUSblog readers know, just over a year ago, the […]

WILMINGTON — Governor Matt Meyer today congratulated Christen Linke Young on her confirmation by the Delaware State Senate as Secretary of the Delaware Department of Health and Social Services (DHSS)....

Palliative and hospice care both focus on improving the quality of life of people with serious illness. In a Q&A, Shelli Feder discusses the future of compassionate care in the U.S. — and what it means to have a “good death.”

The potential use of psychedelic-assisted therapy for adolescents with mental illness has sparked both interest and concern. Modern psychedelic resear…

Leading health law expert Barry R. Furrow of Drexel University and Yale bioethics specialist Stephen R. Latham discussed what happens when private equity comes for hospice care.

This mixed-methods study examines variation in US state-level policies regarding the oversight and regulation of intravenous hydration spas as well as their product offerings, claims, and practices.

This study uses the NHANES database to describe clinical characteristics of Medicaid beneficiaries at risk of disenrollment due to the One Big Beautiful Bill Act’s (HR 1) work requirements, stratified...

Background The clinical and economic impact of breast cancer screening varies based on the modality, frequency, and age of the screened population. Objective To characterize changes in use and cost of breast cancer screening for older women. Design Serial cross-sectional study using data from SEER-Medicare, 2009–2019. Participants Women 67 and older enrolled in Medicare fee-for-service. Main Measures Screening use and cost by age, frequency, and modality. We further categorized screening as cost-effective or cost-ineffective based on published economic analyses rather than guidelines. Cost-effective screening included biennial mammography among women < age 80, while cost-ineffective screening included annual mammography, addition of digital breast tomosynthesis (DBT), screening ultrasound, and any screening among women 80 and older. We estimated total annual spending on screening in Medicare fee-for-service, inflated to 2019 dollars. Key Results Our sample included a mean of 229,683 (range 222,400- 244,793) Medicare beneficiaries annually. Biennial screening was stable among women 65–79, at 11.2% (95% CI 11.0–11.4) in 2009 and 11.9% (95% CI 11.7–12.0) in 2019. Annual screening was also stable at 32.5% (95% CI 32.3–32.7) in 2009 and 30.0% (95% CI 29.8–30.2) in 2019. Among women 80 and older, screening (annual or biennial) declined from 19% (95% CI 18.8–19.3) to 12.9% (95% CI 12.7–13.2). Between 2009–2019, use of DBT rose from 0% to 70.3% of screened women. Total spending on cost-effective screening rose from $569 million per year to $735 million per year, a 29% increase. Spending on cost-ineffective screening rose from $548 million to $1.025 billion, an 87% increase. By 2019, spending on cost-ineffective screening accounted for 58% of total spending. Conclusions Screening costs for older women have risen, driven by expenditures on technologies that may not be cost-effective. Reducing use of low value screening could result in savings that could be reallocated toward high value screening and follow up testing.